{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T10:02:08Z","timestamp":1768039328248,"version":"3.49.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,1,11]],"date-time":"2017-01-11T00:00:00Z","timestamp":1484092800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1038\/nrgastro.2016.201","type":"journal-article","created":{"date-parts":[[2017,1,11]],"date-time":"2017-01-11T05:19:22Z","timestamp":1484111962000},"page":"76-78","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["High-definition PBC: biology, models and therapeutic advances"],"prefix":"10.1038","volume":"14","author":[{"given":"Gwilym J.","family":"Webb","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gideon M.","family":"Hirschfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,1,11]]},"reference":[{"key":"BFnrgastro2016201_CR1","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev-pathol-020712-164014","volume":"8","author":"GM Hirschfield","year":"2013","unstructured":"Hirschfield, G. M. & Gershwin, M. E. The immunobiology and pathophysiology of primary biliary cirrhosis. Annu. Rev. Pathol. 8, 303\u2013330 (2013).","journal-title":"Annu. Rev. Pathol."},{"key":"BFnrgastro2016201_CR2","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1002\/hep.28128","volume":"63","author":"PJ Trivedi","year":"2016","unstructured":"Trivedi, P. J., Corpechot, C., Pares, A. & Hirschfield, G. M. Risk stratification in autoimmune cholestatic liver diseases: opportunities for clinicians and trialists. Hepatology 63, 644\u2013659 (2016).","journal-title":"Hepatology"},{"key":"BFnrgastro2016201_CR3","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1002\/hep.28641","volume":"64","author":"HR Bae","year":"2016","unstructured":"Bae, H. R.  et al. Chronic expression of interferon-gamma leads to murine autoimmune cholangitis with a female predominance. Hepatology 64, 1189\u20131201 (2016).","journal-title":"Hepatology"},{"key":"BFnrgastro2016201_CR4","doi-asserted-by":"publisher","first-page":"8019","DOI":"10.1038\/ncomms9019","volume":"6","author":"HJ Cordell","year":"2015","unstructured":"Cordell, H. J.  et al. International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways. Nat. Commun. 6, 8019 (2015).","journal-title":"Nat. Commun."},{"key":"BFnrgastro2016201_CR5","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/hep.28550","volume":"64","author":"JC Chang","year":"2016","unstructured":"Chang, J. C.  et al. Soluble adenylyl cyclase regulates bile salt-induced apoptosis in human cholangiocytes. Hepatology 64, 522\u2013534 (2016).","journal-title":"Hepatology"},{"key":"BFnrgastro2016201_CR6","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jaut.2016.08.006","volume":"75","author":"S Hisamoto","year":"2016","unstructured":"Hisamoto, S.  et al. Hydrophobic bile acids suppress expression of AE2 in biliary epithelial cells and induce bile duct inflammation in primary biliary cholangitis. J. Autoimmun. 75, 150\u2013160 (2016).","journal-title":"J. Autoimmun."},{"key":"BFnrgastro2016201_CR7","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.jhep.2012.07.008","volume":"57","author":"YH Oo","year":"2012","unstructured":"Oo, Y. H.  et al. CXCR3-dependent recruitment and CCR6-mediated positioning of Th-17 cells in the inflamed liver. J. Hepatol. 57, 1044\u20131051 (2012).","journal-title":"J. Hepatol."},{"key":"BFnrgastro2016201_CR8","doi-asserted-by":"publisher","first-page":"247ra100","DOI":"10.1126\/scitranslmed.3009098","volume":"6","author":"J Luo","year":"2014","unstructured":"Luo, J.  et al. A nontumorigenic variant of FGF19 treats cholestatic liver diseases. Sci. Transl Med. 6, 247ra100 (2014).","journal-title":"Sci. Transl Med."},{"key":"BFnrgastro2016201_CR9","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1002\/hep.28257","volume":"63","author":"M Zhou","year":"2016","unstructured":"Zhou, M.  et al. Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice. Hepatology 63, 914\u2013929 (2016).","journal-title":"Hepatology"},{"key":"BFnrgastro2016201_CR10","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1056\/NEJMoa1509840","volume":"375","author":"F Nevens","year":"2016","unstructured":"Nevens, F.  et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N. Engl. J. Med. 375, 631\u2013643 (2016).","journal-title":"N. Engl. J. Med."}],"container-title":["Nature Reviews Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrgastro.2016.201.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrgastro.2016.201","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrgastro.2016.201.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:55:52Z","timestamp":1684468552000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrgastro.2016.201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,11]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["BFnrgastro2016201"],"URL":"https:\/\/doi.org\/10.1038\/nrgastro.2016.201","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,11]]},"assertion":[{"value":"11 January 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.M.H. has been on primary biliary cholangitis advisory boards for GlaxoSmithKline, Intercept Pharmaceuticals and Novartis. G.M.H. has been a study investigator for CymaBay Therapeutics, Dr Falk Pharma, FF Pharma, GlaxoSmithKline, Gilead, Intercept Pharmaceuticals, NGM Bio, Novartis and Shire.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}